{
  "meta": {
    "title": "Congestive_Heart_Failure",
    "url": "https://brainandscalpel.vercel.app/congestive-heart-failure-29923483.html",
    "scrapedAt": "2025-11-29T18:33:44.134Z"
  },
  "questions": [
    {
      "id": 3588,
      "choices": [
        {
          "id": 14331,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a drug that can act by inhibiting angiotensin converting enzyme</span></span></span></p>"
        },
        {
          "id": 14332,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a drug used in combination with valsartan for congestive heart failure</span></span></span></p>"
        },
        {
          "id": 14333,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypokalemia is an adverse effect of sacubitril</span></span></span></p>"
        },
        {
          "id": 14334,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacubitril is combined with ramipril for treatment of hypertension</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statement is True regarding Sacubitril?</span></span></span></p>",
      "unique_key": "Q1881193",
      "question_audio": null,
      "question_video": null,
      "map_id": 35980,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It is a drug used in combination with valsartan for congestive heart failure</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacubitril</strong> is a <strong>neprilysin inhibitor</strong> that <strong>increases </strong>the levels of <strong>natriuretic peptides </strong>by <strong>inhibiting their degradation</strong>. <strong>Neprilysin</strong> is responsible for <strong>degrading </strong>various peptides including <strong>natriuretic peptides, angiotensin II, bradykinin, and substance P.</strong> To counteract the potential excess of <strong>angiotensin II </strong>due to<strong> neprilysin inhibition, sacubitril </strong>is combined with an<strong> angiotensin receptor blocker (ARB),</strong> specifically <strong>valsartan.</strong> This combination, referred to as an <strong>angiotensin receptor-neprilysin inhibitor (ARNI),</strong> is approved for the treatment of<strong> heart failure. ARNI</strong> is specifically indicated to<strong> reduce the risk of cardiovascular death </strong>and <strong>hospitalization for heart</strong> failure in patients with<strong> chronic heart failure (NYHA Class II-IV) </strong>and<strong> reduced ejection fraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect</strong> because <strong>sacubitril&nbsp;is not an angiotensin converting enzyme (ACE) inhibitor</strong>, which typically have names ending in -pril.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Incorrect </strong>as <strong>hypokalemia</strong>&nbsp;is <strong>not a side effect</strong> associated with <strong>sacubitril.</strong> It is <strong>more</strong> commonly associated with <strong>traditional</strong> <strong>diuretics </strong>rather than<strong> neprilysin inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>sacubitril is combined with valsartan, not ramipril</strong>, and the combination is used for <strong>heart failure,</strong> not specifically for hypertension.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacubitril is a neprilysin inhibitor </strong>used in combination<strong> with valsartan</strong> as an<strong> ARNI for the treatment of heart failure</strong> to <strong>reduce the risk</strong> of <strong>cardiovascular death and heart failure hospitalization</strong>, particularly in patients with<strong> reduced ejection fraction.</strong></span></span></span></p>",
      "correct_choice_id": 14332,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3856,
      "choices": [
        {
          "id": 15403,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine </span></span></span></p>"
        },
        {
          "id": 15404,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
        },
        {
          "id": 15405,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine </span></span></span></p>"
        },
        {
          "id": 15406,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasudil</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs block late inward sodium ion channels?</span></span></span></p>",
      "unique_key": "Q7657781",
      "question_audio": null,
      "question_video": null,
      "map_id": 35989,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Ranolazine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine is known for its unique mechanism of action as a late inward sodium channel blocker. This property allows it to reduce the intracellular accumulation of sodium, which can reduce the calcium overload in cardiac cells through the sodium-calcium exchanger. By doing so, ranolazine helps to improve myocardial relaxation and decreases cardiac ischemia without significantly affecting the heart rate or blood pressure.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Trimetazidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trimetazidine acts as a partial fatty acid oxidation inhibitor, optimizing the energy metabolism of the heart during ischemia, but it does not block sodium channels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ivabradine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, resulting in heart rate reduction, which can be beneficial in conditions like angina and heart failure, but it is not a sodium channel blocker.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fasudil:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fasudil is a Rho-kinase inhibitor with vasodilatory effects and does not block sodium channels.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine is a late inward sodium channel blocker that can be used to treat chronic angina by improving myocardial relaxation and decreasing ischemia without major effects on heart rate or blood pressure.</span></span></span></p>",
      "correct_choice_id": 15403,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3594,
      "choices": [
        {
          "id": 14355,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Candesartan</span></span></span></p>"
        },
        {
          "id": 14356,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aliskiren</span></span></span></p>"
        },
        {
          "id": 14357,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinapril</span></span></span></p>"
        },
        {
          "id": 14358,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Benazepril</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is an oral renin inhibitor?</span></span></span></p>",
      "unique_key": "Q1095275",
      "question_audio": null,
      "question_video": null,
      "map_id": 35983,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Aliskiren&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aliskiren </strong>is an <strong>oral renin inhibitor</strong>, which acts by directly <strong>inhibiting the activity of renin.</strong> Renin is an enzyme that initiates the <strong>renin-angiotensin-aldosterone system (RAAS),</strong> leading to the production of<strong> angiotensin I,</strong> which is then <strong>converted to angiotensin II.</strong> <strong>Angiotensin II</strong> is a <strong>potent vasoconstrictor</strong> and <strong>stimulates aldosterone secretion,</strong> leading to<strong> increased blood pressure.</strong> By <strong>inhibiting</strong> <strong>renin</strong>, aliskiren<strong> reduces</strong> the formation of <strong>angiotensin I and II, </strong>thereby<strong> lowering blood pressure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Candesartan:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Candesartan is an <strong>angiotensin II receptor blocker (ARB)</strong>. It works by<strong> blocking the action of angiotensin II</strong> at its receptor, <strong>preventing angiotensin II </strong>from causing<strong> vasoconstriction and aldosterone</strong> release, which in turn <strong>lowers blood pressure.</strong> It <strong>does not inhibit renin </strong>directly.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Quinapril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinapril is an <strong>angiotensin-converting enzyme (ACE) inhibitor</strong>. It inhibits the enzyme responsible for <strong>converting</strong> <strong>angiotensin I to angiotensin II, </strong>a<strong> potent vasoconstrictor.</strong> By<strong> reducing</strong> the levels of <strong>angiotensin II,</strong> it <strong>lowers blood pressure.</strong> Quinapril acts later in the<strong> RAAS pathway</strong> compared<strong> to aliskiren</strong> and <strong>does not directly inhibit renin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Benazepril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Benazepril is also an <strong>ACE inhibitor,</strong> similar to<strong> quinapril. </strong>It<strong> lowers blood pressure</strong> by<strong> inhibiting </strong>the <strong>conversion of</strong> <strong>angiotensin I to angiotensin II,</strong> thereby <strong>reducing vasoconstriction</strong> and <strong>aldosterone-mediated volume expansion</strong>. Like <strong>quinapril,</strong> <strong>benazepril does not</strong> act by<strong> inhibiting renin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The objective is to understand the <strong>mechanisms of action </strong>of various drugs used in the<strong> management of hypertension,</strong> focusing on their roles within the <strong>renin-angiotensin-aldosterone system.</strong> Recognizing the unique action of <strong>aliskiren as a renin inhibitor,</strong> in <strong>contrast to ARBs and ACE inhibitors</strong> that<strong> act downstream,</strong> is essential for effective <strong>hypertension management. </strong></span></span></span></p>",
      "correct_choice_id": 14356,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3622,
      "choices": [
        {
          "id": 14467,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tolvaptan</span></span></span></p>"
        },
        {
          "id": 14468,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nesiritide</span></span></span></p>"
        },
        {
          "id": 14469,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
        },
        {
          "id": 14470,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drug can be used for treatment of euvolemic hyponatremia in patient with advanced congestive heart failure?</span></span></span></p>",
      "unique_key": "Q9327063",
      "question_audio": null,
      "question_video": null,
      "map_id": 35981,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Tolvaptan&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tolvaptan</strong> is the appropriate drug for treating <strong>euvolemic hyponatremia </strong>in patients with <strong>advanced congestive heart failure (CHF)</strong>. <strong>Euvolemic hyponatremia</strong> is often caused by the<strong> syndrome of inappropriate secretion of antidiuretic hormone (SIADH),</strong> which is characterized by<strong> excessive retention of water</strong> with a <strong>dilutional drop in serum sodium.</strong> <strong>Tolvaptan acts</strong> as an orally active <strong>nonpeptide</strong> <strong>antagonist</strong> of the<strong> vasopressin V2 receptor</strong>, which mediates<strong> water reabsorption in the kidneys.</strong> By <strong>blocking </strong>this receptor, <strong>tolvaptan</strong> <strong>prevents water reabsorption, </strong>leading to an <strong>increase in water excretion, normalization of serum sodium levels</strong>, and <strong>alleviation of</strong> <strong>dyspnea </strong>related to<strong> CHF.</strong> While it is effective for <strong>short-term improvem</strong>ent, there are no noted long-term benefits.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Nesiritide:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as nesiritide is a<strong> recombinant B-type natriuretic peptide</strong> used as a <strong>b</strong> decompensated heart failure, not specifically for<strong> euvolemic hyponatremia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hydrocortisone:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>because <strong>hydrocortisone</strong> is a<strong> corticosteroid </strong>and <strong>does not</strong> address the underlying mechanisms of <strong>euvolemic hyponatremia in CHF.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metoprolol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect </strong>as <strong>metoprolol is a beta-blocker</strong> used in the management of <strong>CHF and hypertension</strong>, but it is <strong>not used</strong> to directly treat<strong> euvolemic hyponatremia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">In patients with <strong>advanced congestive heart failure</strong> presenting with <strong>euvolemic hyponatremia, tolvaptan</strong> is used to <strong>correct water</strong> <strong>retention and hyponatremia associated with SIADH </strong>by <strong>antagonizing the vasopressin V2 receptors</strong> and <strong>increasing water excretion.</strong></span></span></span></p>",
      "correct_choice_id": 14467,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3660,
      "choices": [
        {
          "id": 14619,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a BNP analogue</span></span></span></p>"
        },
        {
          "id": 14620,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used in decompensated CHF</span></span></span></p>"
        },
        {
          "id": 14621,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be administered orally</span></span></span></p>"
        },
        {
          "id": 14622,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It causes loss of Na<sup>+</sup> in the urine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following statements about nesiritide are true except? </span></span></span></p>",
      "unique_key": "Q3052889",
      "question_audio": null,
      "question_video": null,
      "map_id": 35985,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) It can be administered orally</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Nesiritide</strong> is<strong> not </strong>available in an <strong>oral formulation </strong>because it is a <strong>peptide </strong>(<strong>Note</strong>: Drugs ending with <strong>&lsquo;tide&rsquo; are peptides)</strong>. <strong>Nesiritide</strong> is administered<strong> intravenously.</strong> It is a <strong>recombinant</strong> form of <strong>B-type natriuretic peptide (BNP),</strong> which is naturally produced by the <strong>ventricles of the heart.</strong> The <strong>intravenous administration </strong>is necessary because <strong>peptides typically undergo rapid degradation</strong> in the <strong>gastrointestinal tract</strong> and would be ineffective if administered orally.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is a BNP analogue:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true. Nesiritide</strong> is a <strong>synthetic</strong> version of <strong>BNP</strong> that is used in the management of <strong>acute decompensated heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It can be used in decompensated CHF:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. <strong>Nesiritide</strong> is indicated for the <strong>treatment of acute</strong> <strong>decompensated congestive heart failure (CHF),</strong> where it works by causing<strong> vasodilation and natriuresis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It causes loss of Na+ in the urine:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true</strong>. Nesiritide promotes <strong>natriuresis,</strong> which is the<strong> excretion of sodium</strong> in the <strong>urine</strong>, contributing to its <strong>beneficial effects in heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>administration and effects of nesiritide </strong>in the treatment of<strong> acute decompensated heart</strong> <strong>failure</strong>. Nesiritide must be <strong>administered intravenously </strong>due to its <strong>peptide</strong> nature and the <strong>gastrointestinal degradation of oral peptides</strong></span></span></span></p>",
      "correct_choice_id": 14621,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3659,
      "choices": [
        {
          "id": 14615,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">They should be started with optimum doses</span></span></span></p>"
        },
        {
          "id": 14616,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">They should gradually increase over the weeks</span></span></span></p>"
        },
        {
          "id": 14617,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Special precautions should be taken in cases of NYHA class III and IV</span></span></span></p>"
        },
        {
          "id": 14618,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carvedilol and metoprolol are the preferred drugs</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are true about starting beta-blocker therapy in a patient with congestive heart failure except: </span></span></span></p>",
      "unique_key": "Q1070367",
      "question_audio": null,
      "question_video": null,
      "map_id": 35984,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) They should be started with optimum doses.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;In treating patients with <strong>congestive heart failure</strong>, particularly those with an <strong>ejection fraction &lt; 35% </strong>and <strong>NYHA Class II or III</strong> symptoms,<strong> beta-blockers</strong> are recommended alongside <strong>ACE inhibitors or angiotensin-receptor antagonists, and diuretics. </strong>However, <strong>beta-blockers </strong>should be initiated at <strong>very low doses</strong>, often<strong> less than one-tenth</strong> of the target dose. This is contrary to the statement in option a, as starting with <strong>&quot;optimum&quot; doses</strong> could be interpreted as <strong>beginning with the target or final dose</strong>, which is not the recommended approach. For <strong>NYHA Class IIIB and IV patients,</strong> clinicians should proceed with <strong>caution.</strong> <strong>Beta-blockers</strong> should <strong>not</strong> be initiated in recently <strong>decompensated heart failure </strong>until the patient has been<strong> stable for several days to weeks.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Gradually increasing the dose over weeks</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is <strong>correct</strong>, as this allows for the <strong>patient&rsquo;s tolerance to the drug</strong> to build and <strong>minimizes </strong>the <strong>risk of adverse effects. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Special precautions with NYHA class III and IV patients</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are necessary due to their <strong>increased risk of fluid overload </strong>and <strong>worsening heart failure. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Carvedilol and metoprolol</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are indeed the <strong>preferred beta-blockers</strong> for treating <strong>congestive heart failure</strong> due to their proven benefits in this patient population.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">When initiating <strong>beta-blocker </strong>therapy in <strong>congestive heart failure</strong>, it is essential to<strong> start with very low doses and titrate</strong> gradually to <strong>minimize risks</strong>, especially in patients with <strong>more advanced disease (NYHA class III and IV).</strong></span></span></span></p>",
      "correct_choice_id": 14615,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3662,
      "choices": [
        {
          "id": 14627,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It acts by causing prolonged opening of ATP dependent K<sup>+</sup> channels in beta cells</span></span></span></p>"
        },
        {
          "id": 14628,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can cause severe hypoglycemia</span></span></span></p>"
        },
        {
          "id": 14629,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can be used to treat patients with insulinoma</span></span></span></p>"
        },
        {
          "id": 14630,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used as an antihypertensive agent</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about diazoxide is false?</span></span></span></p>",
      "unique_key": "Q7270797",
      "question_audio": null,
      "question_video": null,
      "map_id": 35987,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It can cause severe hypoglycemia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diazoxide</strong> <strong>does not </strong>cause <strong>hypoglycemia</strong>; in fact, it has the opposite effect of causing <strong>hyperglycemia</strong>. The drug acts as a<strong> potassium</strong> <strong>channel opener,</strong> and when it<strong> opens ATP-dependent potassium channels</strong> in the pancreatic beta cells, this action results in <strong>decreased</strong> release of <strong>insulin</strong>. This would lead to <strong>increased blood glucose levels, </strong>which is why<strong> diazoxide can cause hyperglycemia. </strong>Its effect on the <strong>pancreatic beta cells</strong> is utilized therapeutically to treat <strong>insulinoma, </strong>a condition characterized by <strong>excessive insulin secretion,</strong> by <strong>reducing insulin release.</strong> In blood vessels, the<strong> opening of potassium channels causes vasodilation</strong>, which accounts for <strong>diazoxide&rsquo;s use</strong> as an<strong> antihypertensive agent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>true as diazoxide</strong> does cause <strong>prolonged opening of ATP-dependent K+ channels</strong> in pancreatic beta cells, leading to<strong> decreased insulin release. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>True</strong> because<strong> diazoxide </strong>is used in the treatment of<strong> insulinoma </strong>due to its <strong>ability to suppress insulin secretion</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. </span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>True</strong> since <strong>diazoxide</strong> has a<strong> vasodilatory effect </strong>due to its action on<strong> potassium channels in blood vessels, </strong>making it useful as an<strong> antihypertensive agent.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Diazoxide</strong> causes <strong>hyperglycemia</strong>, not hypoglycemia, by i<strong>nhibiting insulin release</strong> through the<strong> opening of K+ channels in pancreatic</strong> <strong>beta cells </strong>and is used in the treatment of <strong>insulinoma</strong> and as an<strong> antihypertensive agent </strong>due to its<strong> vasodilatory action.</strong></span></span></span></p>",
      "correct_choice_id": 14628,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3645,
      "choices": [
        {
          "id": 14559,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lignocaine</span></span></span></p>"
        },
        {
          "id": 14560,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propanolol</span></span></span></p>"
        },
        {
          "id": 14561,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Encainide</span></span></span></p>"
        },
        {
          "id": 14562,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A new antiarrhythmic drug is found to be effective against both atrial and ventricular arrhythmias. Its effect on action potential is shown in the Figure. The effect of this new drug is most like:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-2-min.jpg\" style=\"height:168px; width:400px\" /></span></span></span></p>",
      "unique_key": "Q6413034",
      "question_audio": null,
      "question_video": null,
      "map_id": 35992,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Quinidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>graph</strong> provided<strong> shows an action potential curve </strong>with a<strong> prolonged plateau </strong>phase after<strong> drug therapy,</strong> which is characteristic of a drug that <strong>blocks potassium channels</strong>, thereby<strong> prolonging the duration of the action potential. </strong>The graph also depicts the <strong>decrease</strong> <strong>in slope of phase 0 </strong>which is characteristic of<strong> sodium channel blockers.</strong> This effect (<strong>sodium and potassium channel blockade</strong>) is seen with<strong> Class IA antiarrhythmic drugs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Among the options provided, <strong>Quinidine</strong> is <strong>known to have this effect on the action potential.</strong> Quinidine is a <strong>Class IA antiarrhythmic</strong> drug that <strong>not only blocks sodium channels (like Class I drugs) </strong>but also has the <strong>additional effect</strong> of <strong>blocking potassium channels,</strong> similar to<strong> Class III antiarrhythmics,</strong> which can lead to <strong>a prolonged action potential.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Lignocaine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Lignocaine (Lidocaine) is a <strong>Class IB antiarrhythmic drug</strong> that primarily works by <strong>shortening the action potential</strong> duration by <strong>blocking sodium channels</strong>, particularly in <strong>ischemic or depolarized cells</strong>. It<strong> does not</strong> prolong the <strong>action</strong> <strong>potential plateau.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Propranolol is a<strong> Class II antiarrhythmic</strong>, which is a <strong>beta-blocker </strong>that reduces<strong> sympathetic nervous system</strong> <strong>activity.</strong> It <strong>does not </strong>have a direct effect on the<strong> action potential duration or plateau phase.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Encainide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Encainide</strong>, which is<strong> no longer widely used,</strong> was a<strong> Class IC antiarrhythmic drug </strong>that significantly slows conduction by<strong> blocking sodium channels</strong> but <strong>does not </strong>typically prolong the<strong> action potential duration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to recognize the<strong> electrophysiologic effects of antiarrhythmic drugs</strong> on the cardiac action potential. Understanding how these drugs affect the <strong>action potential</strong> can provide insights into their <strong>therapeutic uses and potential</strong> <strong>arrhythmogenic risks. Quinidine&#39;s</strong> effect of <strong>prolonging the action potential duration</strong> is useful in the treatment of <strong>both atrial and</strong> <strong>ventricular arrhythmias,</strong> but it also carries the<strong> risk of proarrhythmia, </strong>underlining the need for<strong> careful patient selection </strong>and <strong>monitoring.</strong></span></span></span></p>",
      "correct_choice_id": 14562,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3580,
      "choices": [
        {
          "id": 14299,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nesiritide</span></span></span></p>"
        },
        {
          "id": 14300,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacubitril</span></span></span></p>"
        },
        {
          "id": 14301,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
        },
        {
          "id": 14302,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used for treatment of congestive heart failure except:</span></span></span></p>",
      "unique_key": "Q3873872",
      "question_audio": null,
      "question_video": null,
      "map_id": 35991,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Trimetazidine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Trimetazidine is an anti-anginal medication</strong> that <strong>improves myocardial glucose utilization </strong>by <strong>inhibiting fatty acid metabolism, </strong>leading to an <strong>energy-sparing effect in ischemic cells</strong>. However, it is <strong>not used </strong>in the treatment of <strong>congestive heart failure (CHF)</strong>; its <strong>primary use</strong> is in the management of <strong>angina pectoris.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Nesiritide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Nesiritide is a<strong> recombinant B-type natriuretic peptide</strong> that has <strong>vasodilatory effects </strong>and is used in the management of<strong> acute decompensated heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sacubitril:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> When<strong> combined with valsartan</strong> (a <strong>neprilysin inhibitor and an angiotensin II receptor blocker, </strong>respectively), sacubitril is used to<strong> reduce the risk of cardiovascular death </strong>and<strong> hospitalization for heart failure in patients</strong> with <strong>chronic heart</strong> <strong>failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Metoprolol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Metoprolol is a<strong> beta-blocker </strong>that is used in the management of<strong> CHF.</strong> It <strong>reduces myocardial oxygen demand</strong> and can <strong>improve survival in patients with heart failure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-094413.png\" style=\"height:849px; width:1000px\" /></span></u></strong></span></span></p>",
      "correct_choice_id": 14301,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3735,
      "choices": [
        {
          "id": 14919,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Digoxin</span></span></span></p>"
        },
        {
          "id": 14920,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Furosemide</span></span></span></p>"
        },
        {
          "id": 14921,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metoprolol succinate</span></span></span></p>"
        },
        {
          "id": 14922,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dobutamine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following medications has been shown to reduce mortality in heart failure with reduced ejection fraction?</span></span></span></p>",
      "unique_key": "Q9131620",
      "question_audio": null,
      "question_video": null,
      "map_id": 35990,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Metoprolol succinate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Metoprolol succinate</strong>, a <strong>beta-1 selective adrenergic receptor blocker,</strong> has been shown in clinical trials to<strong> reduce mortality in patients</strong> with heart failure with reduced ejection fraction (HFrEF). It works by reducing the effects of <strong>catecholamines (stress</strong> <strong>hormones) on the heart, </strong>which in the setting of <strong>heart failure can be detrimental over time</strong>. By<strong> decreasing heart rate and myocardial</strong> <strong>contractility, </strong>it <strong>reduces myocardial oxygen demand </strong>and can<strong> improve the function of the heart.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Digoxin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While digoxin can<strong> improve symptoms and reduce hospitalizations by increasing the force of cardiac c</strong>ontractions and <strong>controlling heart rate</strong> in patients with <strong>heart failure,</strong> it<strong> has not been shown to reduce mortality </strong>in these patients.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Furosemide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Furosemide is a<strong> loop diuretic</strong> that is used to<strong> reduce symptoms of congestion in heart failure </strong>by promoting the<strong> excretion of sodium and water</strong>. However, it <strong>does not</strong> have a<strong> direct effect on reducing mortality in heart failure</strong> with <strong>reduced</strong> <strong>ejection fraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Dobutamine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dobutamine is a<strong> beta-1 agonist</strong> used in <strong>acute heart failure to increase cardiac output</strong>. It is generally used for <strong>short-term support in hospitalized patients</strong> and is <strong>not </strong>shown to<strong> reduce long-term mortality in chronic heart failure</strong>; its long-term use can actually be<strong> harmful due to increased cardiac oxygen demand </strong>and potential for<strong> arrhythmia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the role of <strong>different classes of drugs </strong>in the treatment of <strong>heart failure</strong> with <strong>reduced ejection</strong> <strong>fraction,</strong> particularly those that <strong>have been demonstrated to reduce mortality.</strong> </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs reducing mortality in CHF include:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta blockers</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACE inhibitors</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ARBs</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aldosterone antagonists</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydralazine + Isosorbide dinitrate</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 14921,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3629,
      "choices": [
        {
          "id": 14495,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary fibrosis</span></span></span></p>"
        },
        {
          "id": 14496,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corneal microdeposits</span></span></span></p>"
        },
        {
          "id": 14497,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Photosensitivity</span></span></span></p>"
        },
        {
          "id": 14498,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tachycardia</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following are adverse effects of amiodarone except:</span></span></span></p>",
      "unique_key": "Q9450596",
      "question_audio": null,
      "question_video": null,
      "map_id": 35986,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Tachycardia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a <strong>class III anti-arrhythmic</strong> drug known for its <strong>broad spectrum of action</strong>. <strong>Tachycardia is not an adverse effect</strong> of amiodarone; rather, the drug can <strong>cause bradycardia </strong>and may<strong> lead to a fall in blood pressure </strong>and <strong>myocardial depression</strong> when administered <strong>intravenously.</strong> This medication is <strong>notorious for a number of serious advrsee effects</strong>, particularly with <strong>prolonged use.</strong> The most severe include<strong> pulmonary fibrosis and alveolitis.</strong> <strong>Photosensitivity and skin pigmentation</strong> may occur in approximately 10% of patients taking amiodarone.<strong> Corneal microdeposits</strong> can result in <strong>vision disturbance</strong>s such as <strong>seeing halos around light</strong>s, commonly described as <strong>headlight dazzle,</strong> but this <strong>side effect is reversible upon discontinuation of the drug. </strong>Amiodarone may also cause<strong> peripheral neuropathy,</strong> which often presents as <strong>muscle weakness in the pelvic and shoulder regions</strong>. Additionally, it can <strong>interfere with thyroid function</strong> by <strong>preventing the peripheral conversion of thyroxine (T4) to triiodothyronine (T3), </strong>leading to <strong>hypothyroidism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pulmonary fibrosis:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a<strong> serious and well-recognized side effect of amiodarone,</strong> especially with <strong>long-term use.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Corneal microdeposits:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Common </strong>and typically <strong>reversible upon discontinuation of the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Photosensitivity:&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">This<strong> adverse effect</strong> can occur in patients taking amiodarone<strong>, leading to increased risk of sunburn and skin</strong> <strong>pigmentation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Amiodarone</strong> is a <strong>class III anti-arrhythmic drug</strong> associated with <strong>several adverse effects </strong>including <strong>pulmonary fibrosis, corneal</strong> <strong>microdeposits, and photosensitivity,</strong> but not tachycardia; <strong>in fact, it more commonly causes bradycardia.</strong></span></span></span></p>",
      "correct_choice_id": 14498,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3837,
      "choices": [
        {
          "id": 15327,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Procainamide</span></span></span></p>"
        },
        {
          "id": 15328,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flecanide</span></span></span></p>"
        },
        {
          "id": 15329,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Quinidine</span></span></span></p>"
        },
        {
          "id": 15330,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sotalol</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are likely to produce the following ECG abnormality except: </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/49.jpg\" style=\"height:175px; width:500px\" /></span></span></span></p>",
      "unique_key": "Q9547037",
      "question_audio": null,
      "question_video": null,
      "map_id": 35982,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Flecainide</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> ECG </strong>provided shows<strong> polymorphic ventricular tachycardia,</strong> also known as <strong>Torsades de pointes</strong>. This type of arrhythmia can arise from the b<strong>lockade of cardiac potassium (K) channels,</strong> which is a known <strong>side effect</strong> of certain <strong>classes of antiarrhythmics.</strong> Specifically, <strong>Class Ia antiarrhythmics like Quinidine and Procainamide,</strong> and<strong> Class III antiarrhythmics such as Amiodarone, Sotalol, Ibutilide, </strong>and <strong>Dofetilide, </strong>have been associated with the <strong>occurrence of Torsades de pointes</strong> due to their potential to <strong>prolong the QT interval </strong>on the <strong>ECG.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Procainamide:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Procainamide is a <strong>Class Ia antiarrhythmic</strong> that can<strong> block cardiac potassium channels</strong>, which may lead to <strong>QT prolongation </strong>and the potential development of<strong> Torsades de pointes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Quinidine:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Quinidine, also a <strong>Class Ia antiarrhythmic,</strong> has similar effects on<strong> potassium channels</strong> and can cause <strong>QT</strong> <strong>prolongation and Torsades de pointes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Sotalol:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sotalol is a<strong> Class III antiarrhythmic</strong> that can cause<strong> QT prolongation</strong> and is known to be associated with the <strong>risk of</strong> <strong>Torsades de pointes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Flecainide, a Class Ic antiarrhythmic</strong>, primarily affects<strong> sodium channels</strong> and is<strong> less likely </strong>to cause<strong> QT prolongation,</strong> making it <strong>less</strong> likely to be associated with <strong>Torsades de pointes </strong>compared to the other drugs listed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Flecainide</strong>, a <strong>Class Ic antiarrhythmic</strong> drug, is <strong>unlikely to cause QT prolongation </strong>and <strong>Torsades de pointes</strong> <strong>compared to Class Ia and III</strong> drugs, which can<strong> prolong the QT interval</strong> and are implicated in this<strong> arrhythmia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-123410.png\" style=\"height:488px; width:1000px\" /></span></span></span></p>",
      "correct_choice_id": 15328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3808,
      "choices": [
        {
          "id": 15211,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fasudil</span></span></span></p>"
        },
        {
          "id": 15212,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranolazine</span></span></span></p>"
        },
        {
          "id": 15213,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trimetazidine</span></span></span></p>"
        },
        {
          "id": 15214,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ivabradine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is a Rho kinase inhibitor?</span></span></span></p>",
      "unique_key": "Q4232288",
      "question_audio": null,
      "question_video": null,
      "map_id": 35978,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Fasudil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fasudil </strong>is a <strong>Rho kinase inhibitor. </strong>Rho kinase is an<strong> enzyme</strong> that plays a significant role in<strong> smooth muscle contraction </strong>and other <strong>cellular processes</strong>. <strong>Inhibition</strong> of <strong>Rho kinase</strong> by <strong>fasudil </strong>leads to<strong> vasodilation</strong> making it useful for treatment of<strong> angina pectoris. </strong>It is also being investigated for the treatment of various <strong>cardiovascular disorders, including hypertension and pulmonary arterial</strong> <strong>hypertension, </strong>as well as for the<strong> prevention of cerebral vasospasm </strong>following<strong> subarachnoid hemorrhage.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ranolazine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ranolazine is an<strong> anti-anginal medication. </strong>It works by<strong> inhibiting the late phase of the sodium </strong>current in the <strong>cardiac myocytes</strong>, thus <strong>reducing intracellular calcium overload </strong>and <strong>myocardial oxygen consumption.</strong> It <strong>does not</strong> act as a<strong> Rho kinase</strong> <strong>inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Trimetazidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Trimetazidine is an <strong>anti-ischemic (anti-anginal) metabolic agent</strong> that <strong>improves myocardial glucose</strong> utilization through<strong> inhibition of fatty acid metabolism.</strong> This action helps to<strong> maintain energy production in ischemic heart cells.</strong> <strong>Trimetazidine is not a Rho kinase inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Ivabradine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ivabradine is a<strong> heart rate-reducing agent</strong> that works by<strong> inhibiting the If (funny) channel in the sinoatrial node</strong> <strong>of the heart</strong>, leading to a <strong>reduction in heart rate and myocardial oxygen demand.</strong> It is used for the treatment of <strong>chronic heart failure</strong> and <strong>stable angina pectoris</strong> in patients who<strong> cannot take beta-blockers</strong>. <strong>Ivabradine is not a Rho kinase inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the<strong> different mechanisms of action </strong>of various <strong>anti-anginal drugs. Fasudil as a Rho kinase</strong> <strong>inhibitor contrasts </strong>with<strong> ranolazine, trimetazidine, and ivabradine, </strong>which have different mechanisms. </span></span></span></p>",
      "correct_choice_id": 15211,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3745,
      "choices": [
        {
          "id": 14959,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Coronary vasodilation</span></span></span></p>"
        },
        {
          "id": 14960,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease heart rate</span></span></span></p>"
        },
        {
          "id": 14961,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased afterload</span></span></span></p>"
        },
        {
          "id": 14962,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreases preload</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary mechanism of action of nitrates in a patient of classical angina is:&nbsp;</span></span></span></p>",
      "unique_key": "Q4287837",
      "question_audio": null,
      "question_video": null,
      "map_id": 35979,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Decreases preload</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>primary action of nitrates</strong> in the treatment of <strong>classical angina</strong> is <strong>to decrease preload</strong>. <strong>Nitrates</strong> cause<strong> venous dilation,</strong> which reduces the <strong>volume of blood returning to the heart.</strong> This action <strong>decreases the heart&#39;s workload</strong> and its <strong>demand for oxygen,</strong> thereby <strong>alleviating the symptoms of angina</strong>. Please note, if nothing is mentioned in question, angina should be considered as classical angina.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Coronary Vasodilation</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:<strong> Nitrates do </strong>cause some <strong>coronary vasodilation,</strong> but this is <strong>not their primary action</strong> in treating <strong>classical angina.</strong> <strong>Endothelium independent coronary vasodilation</strong> is the <strong>primary </strong>mechanism of <strong>nitrates </strong>in treatment of <strong>variant</strong> <strong>angina.</strong>&nbsp;In a typical vascular system, the<strong> endothelium</strong> plays a crucial role in <strong>regulating blood vessel tone and blood flow</strong>. It does this by releasing substances like<strong> nitric oxide (NO), </strong>which<strong> promote vasodilation.</strong>&nbsp;However, <strong>nitrates work independently of the endothelial</strong> <strong>cells.</strong> They are<strong> converted into nitric oxide (NO)</strong> <strong>within</strong> the <strong>smooth muscle cells.</strong> This<strong> NO</strong> then activates an enzyme called <strong>guanylate cyclase</strong>, which <strong>increases the levels of cyclic guanosine monophosphate (cGMP).</strong> The <strong>increase in cGMP </strong>leads to relaxation of the<strong> smooth muscle cells</strong>, resulting in <strong>vasodilatio</strong>n. This mechanism is particularly important in conditions like <strong>variant angina,</strong> where there are<strong> episodes of coronary artery spasm</strong>. <strong>Nitrate</strong>s can effectively <strong>relax the smooth muscle </strong>in the<strong> coronary arteries,</strong> <strong>reducing the spasm</strong> and thus <strong>alleviating the angina pain</strong>. This action is <strong>independent </strong>of the <strong>endothelium,</strong> which may <strong>not </strong>be <strong>functioning optimally </strong>in all individuals with <strong>coronary artery disease.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Decrease Heart Rate</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Nitrates <strong>do not</strong> have a significant effect on<strong> heart rate. </strong>Drugs that <strong>primarily decrease heart rate</strong>, such as <strong>beta-blockers</strong>, are used separately for this purpose in the management of angina.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Decrease Afterload</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: While<strong> nitrates</strong> can have a <strong>minor effect on afterload </strong>due to <strong>systemic vasodilation</strong>, <strong>decreasing</strong> <strong>afterload</strong> is <strong>not </strong>their primary mechanism of action in<strong> treating angina</strong>. Medications like <strong>ACE inhibitors or angiotensin receptor</strong> <strong>blockers</strong> are<strong> more </strong>effective for this purpose.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mechanism of action of nitrates</strong> in <strong>classical angina is decrease in preload.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mechanism of action of nitrates</strong> i<strong>n variant angina</strong> is<strong> endothelium independent coronary vasodilation.</strong></span></span></span></li>\r\n</ul>",
      "correct_choice_id": 14962,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 3722,
      "choices": [
        {
          "id": 14867,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Guanylyl cyclase</span></span></span></p>"
        },
        {
          "id": 14868,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phosphokinase 1,2</span></span></span></p>"
        },
        {
          "id": 14869,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase A</span></span></span></p>"
        },
        {
          "id": 14870,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase B</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sodium nitroprusside acts by stimulation of?</span></span></span></p>",
      "unique_key": "Q5804759",
      "question_audio": null,
      "question_video": null,
      "map_id": 35988,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Guanylyl cyclase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sodium nitroprusside</strong> acts by directly <strong>stimulating guanylyl cyclase </strong>in<strong> vascular smooth muscle cells</strong>. This stimulation leads to an <strong>increase in intracellular cyclic guanosine monophosphate (cGMP),</strong> which then <strong>activates protein kinase G (PKG).</strong> The <strong>activation </strong>of <strong>PKG</strong> results in the <strong>dephosphorylation of myosin light chains</strong> in the smooth muscle, which <strong>induces relaxation and vasodilation. </strong>Due to this mechanism, <strong>sodium nitroprusside </strong>is effective in <strong>rapidly reducing blood pressure </strong>in <strong>hypertensive emergencies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Phosphokinase 1,2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There is<strong> no </strong>enzyme specifically named <strong>phosphokinase 1,2. </strong>This option <strong>does not</strong> relate to the known mechanism of action of sodium nitroprusside.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Phospholipase A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Phospholipase A is an enzyme </strong>that <strong>hydrolyzes phospholipids</strong> to produce <strong>fatty acids</strong> and <strong>lysophospholipids</strong>. It is<strong> not </strong>directly involved in the <strong>mechanism of action of sodium nitroprusside.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phospholipase B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Phospholipase B also <strong>acts on phospholipids </strong>but is<strong> not</strong> related to the<strong> vasodilatory action of sodium</strong> <strong>nitroprusside.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the <strong>pharmacodynamics of sodium nitroprusside</strong>, a <strong>potent vasodilator. </strong>By knowing that its mechanism involves th<strong>e stimulation of guanylyl cyclase </strong>and the subsequent<strong> increase in cGMP, </strong>healthcare professionals can better anticipate its effects and necessary precautions, such as <strong>monitoring for signs of cyanide toxicity</strong> due to its metabolism. Understanding the<strong> differences in mechanisms</strong> among various<strong> vasodilators </strong>is crucial for <strong>selecting the appropriate agent </strong>in clinical scenarios.</span></span></span></p>",
      "correct_choice_id": 14867,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}